S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer.

S-1 (also known as TS-1; Taiho Pharmaceutical Co. Ltd.; Tokyo, Japan) is a new oral fluoropyrimidine formulation that combines tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate in a molar ratio of 1:0.4:1. Single-agent S-1 has demonstrated marked activity against non-small-cell lung cancer (NSCLC) as well as a broad array of other solid tumors, including gastric, colorectal, breast, cervical, and pancreatic cancers. This comprehensive review summarizes the results of previous clinical studies and describes ongoing clinical trials of S-1 in advanced NSCLC. S-1 combined with platinum compounds, irinotecan, and gemcitabine has produced promising results in terms of feasibility, safety, and effectiveness. Available data have stimulated further research, including phase III trials for the first-line treatment of advanced NSCLC.
AuthorsIsamu Okamoto, Masahiro Fukuoka
JournalClinical lung cancer (Clin Lung Cancer) Vol. 10 Issue 4 Pg. 290-4 (Jul 2009) ISSN: 1938-0690 [Electronic] United States
PMID19632949 (Publication Type: Journal Article, Review)
Chemical References
  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Administration, Oral
  • Antimetabolites, Antineoplastic (administration & dosage)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy)
  • Clinical Trials as Topic
  • Drug Combinations
  • Humans
  • Japan
  • Lung Neoplasms (drug therapy)
  • Oxonic Acid (administration & dosage)
  • Tegafur (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: